Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human serum albumin (HSA) is the most abundant plasma protein and serves as a key transporter of metal ions, notably copper (Cu(II)), in blood. Roughly 15% of circulating plasma copper is bound to albumin, with the remainder mainly associated with ceruloplasmin (70%) and alpha-2-macroglobulin (10%). Albumin binds Cu(II) with high affinity at its amino-terminal site, forming a labile pool readily exchangeable with cellular transporters such as copper transporter 1 (Ctr1). This copper pool is essential for distribution and homeostasis, but HSA–copper is not itself a conventional pharmacological target[2][3][6][1]. Albumin–copper interactions play important roles in detoxifying redox-active copper and delivering copper to tissues, and are relevant for understanding oral copper uptake, inherited copper metabolism disorders, and the pharmacodynamics of certain copper-chelating anticancer drugs[1][2][4][6].
Chelation and removal of Cu(II) from albumin binding site
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human serum albumin–copper complex.